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10% of all cancer-related deaths in the United States.1
Colorectal oncogenesis follows the classic dysplasia-
adenoma-carcinoma sequence as genetic mutations accu-
mulate in the colonic epithelium,2 and, as malignant tumors
progress, they associate with nodal and distant metastatic
disease. Most deaths occur in patients with late-stage
tumors, which are usually incurable.3,4 Therefore, the
discovery of biomarkers for early detection and of potential
targets for colorectal prevention is an important research
priority.
Human chromosomal segregation 1-like (CSE1L) gene,
alias human cellular apoptosis susceptibility and exportin-
2 gene, is located on chromosome 20q13. CSE1L is
implicated in the regulation of multiple cellular mecha-
nisms, including the mitotic spindle checkpoint, as well as
proliferation and apoptosis, two opposing processes thatstigative Pathology. Published by Elsevier Inc
Y-NC-ND license (http://creativecommons.orgare tightly linked in mammalian cells.5 The CSE1L gene
consists of 25 exons and encodes a protein of 100-kDa
molecular weight. This protein is usually found in the
cytoplasm and nuclei of cells. It functions as a key
component in cytoplasmic-to-nuclear transport and is in
charge of the translocation of importin-a from the nucleus
to the cytoplasm to be recycled and used again in the
nuclear protein import pathway.6 Defects in CSE1L lead to.
/licenses/by-nc-nd/4.0).
Pimiento et alabnormal chromosome segregation, as suggested by the
observation that the locus where this gene resides is a
region frequently harboring ampliﬁcations, aneuploidies,
or aberrant chromosomes that are frequently observed in
cancer cells.7 In addition, CSE1L has been reported to be
highly expressed in a variety of cancer types and to
positively correlate with tumor grade and worse
outcome.5,8
CSE1L has also been shown to have a role in apoptosis,
with studies showing that increased CSE1L protein
expression facilitates apoptosis induced by cypermethrin9
and chemotherapeutic agents.10 It has been observed that,
although CSE1L protein enhances the apoptotic effect of
doxorubicin, 5-ﬂuorouracil, cisplatin, and 4OH-tamoxifen,
the same protein decreases apoptosis induced by paclitaxel
in colon cancer tumor cells.10
CSE1L mRNA expression in colorectal cancer shows
a signiﬁcant correlation with 20q DNA copy number
status. CSE1L protein expression is not associated with
20q gain.11 The expression of CSE1L mRNA and pro-
tein in human colorectal cancer resection specimens and
its role in the progression of colorectal cancer are
currently being investigated. Zhu et al5 examined the
expression levels of CSE1L mRNA using semi-
quantitative RT-PCR. CSE1L expression in the human
colon cancer cell line RKO was knocked down using a
lentivirus-mediated siRNA. The inhibition of expression
in RKO cells caused cell cycle arrest and decreased cell
colony formation and apoptosis.
The effect of CSE1L on the viability, adhesion, and
migration of colorectal cancer cell lines HCT116 and
SW480 has been previously reported. It was shown that
CSE1L depletion via siRNA knockdown signiﬁcantly
reduced the adhesive capacity of HCT116 and SW480,
decreasing their proliferation and inducing apoptosis.12
In this study, we assessed the expression of CSE1L at the
mRNA and protein level in a subset of human colorectal
cancers, as compared to adenomas and normal mucosa. The
CSE1L mRNA expression levels were evaluated against
three publicly available data sets (accession numbers
GSE4183, GSE8671, and GSE14333) retrieved from the
Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.
nih.gov/geo). We show evidence that CSE1L protein
expression increases signiﬁcantly in the early stages of
colorectal cancer progression. We also observed a shift in
CSE1L cellular localization during the transition from ade-
nomas to carcinomas. Moreover, we evaluated the func-
tional role of this protein in select colorectal cancer cell lines
(HCT115, HT29, and SW480) through the knockdown of
its expression by shRNA.
Materials and Methods
This study was approved by the Institutional Review Board
at the H. Lee Mofﬁtt Cancer Center and Research Institute
(Tampa, FL).2762Selection of Human Tissues
Using human colorectal cancer tissue microarrays (TMAs)
(prepared at the Mofﬁtt Cancer Center Tissue Core Facility),
150 tissue samples were analyzed for CSE1L expression by
immunohistochemistry. The tissue samples included 88
(59%) colorectal cancers (CRCs), 40 (27%) histologically
normal colonicmucosa (NR), and 22 (15%) adenomas (ADs).
The diagnosis of the tissues included on the TMA was
conﬁrmed by a senior pathologist (D.C.) with experience in
gastrointestinal pathology. The tumors were staged using the
Astler-Coller modiﬁcation of the Duke’s classiﬁcation.
Tumors occurring in patients with genetic cancer
syndromes as well as arising in the background of inﬂam-
matory bowel disease were excluded from the study. The
NR samples were taken near the resected colorectal margin,
away from the tumor site, from the CRC colon resection
specimens included in this study.TMA Design
The colon 1 TMAwas generated at the Mofﬁtt Cancer Center
Tissue Core and for this study it contained core samples from
40 histologically normal colon, 22 colonic adenomas, 88
colon adenocarcinoma, and 26 human colon cancer cell lines.
The hematoxylin and eosin slides corresponding to the sam-
ples were ﬁrst examined by two pathologists (K.G.N. and
D.C.) to conﬁrm the type of tissue (normal colon, adenoma, or
adenocarcinoma) and to outline with a permanent marker the
tissue area to be sampled for the TMA. For the TMA con-
struction, 1 mm in diameter cores were sampled from the
original formalin-ﬁxed, parafﬁn-embedded tissue block, with
cores taken at each sampling from the area previously outlined
by the pathologists. These cores were then implanted into the
recipient TMA using a Tissue Arrayer (Beecher Instruments,
Inc., Sun Prairie,MI) to produce the colon TMAblock. Tissue
sections from this TMA were then subjected to the CSE1L
immunostain. The colon 1 TMA data, including TMA maps
and raw scores, are provided in Supplemental Table S1 (de-
tails of tissues included), Supplemental Table S2 (map), and
Supplemental Table S3 (raw immunohistochemistry scores).Immunohistochemistry
The tissues were stained for CSE1L using a rabbit poly-
clonal antibody (4C overnight; dilution, 1:300; Spring
Bioscience, Pleasanton, CA). The CSE1L-stained TMAs
were examined by two independent observers (D.C. and
E.H.-J.) experienced in immunohistochemical methods, and
a consensus score was reached for each sample. CSE1L was
scored into four grades, according to the intensity: 0, 1þ,
2þ, and 3þ. The percentage of CSE1L-positive cells was
also scored into four categories: 0 (0%), 1 (1% to 33%), 2
(34% to 66%), and 3 (67% to 100%). The product of the
intensity by percentage scores was used as the ﬁnal scoreajp.amjpathol.org - The American Journal of Pathology
CSE1L in Colorectal Cancer Progressionand was classiﬁed as follows: 0 indicates negative; 1 to
3, weak; 4 to 6, moderate; and 7 to 9, strong.
Statistical Analysis
Descriptive statistics for the scores were generated and
reported for each tissue group. The initial method used to
compare CSE1L expression in CRC and NR was the one-
way analysis of variance. Tukey’s honestly signiﬁcant dif-
ference method was used to adjust P value for pair-wise
comparison. Spearman correlation was used to test any
correlation between CSE1L score and tumor grade and
stage. A Cox proportional hazard model was used to test
whether CSE1L was associated with overall survival and
disease-free survival. All statistical analyses were two-sided
and considered signiﬁcant at P < 0.05.
mRNA Microarray Analysis
To evaluate whether the variation in CSE1L protein
expression between NR and CRC reﬂected a corresponding
modulation of CSE1L mRNA, gene expression was tested
in three publicly available data sets arrayed on the Affy-
metrix HG-U133 þ 2.0 GeneChip. These data sets are
described below and include GEO data sets GSE8671,
GSE4183, and GSE14333. The probe set 201112_s_at was
selected as the best representative on the basis of transcript-
level sequence matching to the National Center for
Biotechnology Information Reference Sequence13
NM_001316 using the IGB tool.14 The R statistical soft-
ware was used for expression analysis (freely available open
source statistical package: www.r-project.org, last accessed
September 2010). GSE418315,16 involves a comparison of
NR, AD, and CRC and tissue from patients with irritable
bowel syndrome from biopsies. These data were MAS5.0
normalized and scaled to 500, and the CSE1L probe set
(201112_s_at) was tested for differences in expression (NR
versus AD; and NR versus CRC). The Mann-Whitney test
was used. Expression plots are displayed after log2 trans-
formation as mean and SEM. GSE8671 is a comparison of
matched normal colon mucosa and adenomas.17 The
expression data were MAS5.0 normalized, scaled to 500,
and log2 transformed. Statistically signiﬁcant differences in
CSE1L expression were tested using a Wilcoxon signed-
rank test for paired samples. The fold-changes between
adenoma and normal colon mucosa were represented in bar
graphs. GSE1433318 is a study of 290 primary colorectal
cancer tumors of different stages. The Mofﬁtt subset of
these cases (n Z 205) was used together with 10 normal
colon mucosa samples from patients treated at the Mofﬁtt
Cancer Center under a University of South Florida Institu-
tional Review Boardeapproved protocol. The expression
data were MAS5.0 normalized, scaled to 500, and log2
transformed. Differences were tested between normal and
tumor (all stages). Data were visualized using mean and
SEM.The American Journal of Pathology - ajp.amjpathol.orgCellular Studies
Cell Culture and shRNA Treatment
Human colon cancer cells HCT116, SW480, and HT29 were
acquired from ATCC (Manassas, VA) and grown in Dul-
becco’s modiﬁed Eagle’s medium and McCoy 5A media
with 10% fetal bovine serum, 50 IU/mL penicillin, and 50
mg/mL streptomycin. The cells were cultured at 37C in a
humidiﬁed atmosphere of 5% CO2. HCT116, HT29, and
SW480 cells in OPTI-MEM medium (Life Technologies,
Carlsbad, CA) were seeded in 6-well plates and cultured at
37C in a humidiﬁed atmosphere of 5% CO2 to get 70%
conﬂuence. Then, cells were treated with scrambled shRNA
(SC-108080), CSE1L shRNA (SC-29908-v; Santa Cruz
Biotechnology, Dallas, TX) using Polybrene reagent
(SC-134220), and incubated at 37C in a humidiﬁed
atmosphere of 5% CO2 for 48 hours. After 48 hours, the cells
were harvested and used for proliferation, colony formation,
and apoptosis assays.
Proliferation Assay
Cells transfected with CSE1L shRNA, scrambled shRNA,
and reagent were seeded in 96-well plates at a density of
3000 cells per well in Dulbecco’s modiﬁed Eagle’s medium
and McCoy 5A media and allowed to grow for 72 hours at
37C in a humidiﬁed atmosphere of 5% CO2. After 72
hours, media were aspirated and replaced with 20 mL of 1
mg/mL MTT and incubated for 2 to 4 hours at 37C in a
humidiﬁed atmosphere of 5% CO2. Media were aspirated,
200 mL of dimethyl sulfoxide was added to each well, plates
were incubated for 5 minutes with shaking, and absorbance
was read at 540 nm.
Soft Agar Colony Formation Assay
A standard soft agar colony formation assay was performed
in CSE1L shRNA, scrambled shRNA, and reagent-treated
cells. The cells were seeded at a density of 5000 per well in
a 12-well plate in 0.3% agar over a 0.6% bottom agar layer.
Colonies were fed with growth media and the drugs
(5  105 mol/L), and growth of colony formation was
observed for 10 to 14 days. Colonies were photographed
after overnight incubation with 1 mg/mL MTT in the wells.
The colonies were counted under stereomicroscope. The
experiments were performed at least twice, each in triplicate.
Apoptosis Assay
The cytoplasmic DNA fragments and histones were detected
in the cells treated with CSE1L shRNA, scrambled shRNA,
and reagent using Cell Death Detection enzyme-linked
immunosorbent assay kit (Roche Diagnostic, Indianapolis,
IN), as per the manufacturer’s instructions. Standard soft
agar colony formation assays were performed in HCT116,
SW480, and HT29 cells, and the cells were treated with
scrambled or CSE1L shRNA. The cells were seeded at a
density of 5000 per well in a 12-well plate in 0.3% agar over
a 0.6% bottom agar layer. Colonies were fed with 10%2763
Table 1 Baseline Patient Characteristics (n Z 88)
Characteristic Value
Age (years)
Range 24-92
Mean 64
Sex
Male 48
Female 40
Tumor size (cm)
Range 1.4-14.5
Mean 5.2
Tumor grade
LG 73
HG 15
Pathological stage
I 3
II 32
III 37
IV 16
HG, high-grade dysplasia; LG, low-grade dysplasia.
Pimiento et alenriched media and were observed for 14 days. Colonies
were photographed after overnight incubation with 1
mg/mL MTT in the wells. The colonies were counted underFigure 1 mRNAexpression analysis of CSE1L in colorectal carcinoma (CRC) tissue
human colonic mucosa (NR) and adenomas (ADs) or NR and CRC (PZ 0.02).B: CSE1L
A, B, C, and D) in a large cohort of CRC patients. C: CSE1L mRNA expression is signi
2764stereomicroscope and compared with control. The experi-
ments were performed at least twice, each in triplicate.Western Blot Analysis
Proteins were extracted from cells using radio-
immunoprecipitation assay buffer with protease inhibitor.
Total protein (40 mg) was resolved on 12.5% SDS-PAGE
running gel and a 5% stacking gel. Proteins were then
electrotransferred onto nitrocellulose membranes. After
blocking in 5% nonfat powdered milk for 1 hour, the
membranes were washed and then treated with antibodies to
CSE1L (CAS) and b-actin (1:1000 and 1:5000, respec-
tively) overnight at 4C (Santa Cruz Biotechnology, Santa
Cruz, CA). After washing, blots were incubated with
horseradish peroxidaseeconjugated secondary antibody IgG
(1:5000) for 1 hour at room temperature. The washed blot
was then treated with SuperSignal West Pico chemilumi-
nescent substrate (Pierce Biotechnology, Rockford, IL) for
positive antibody reaction. Membranes were exposed to
X-ray ﬁlm (Eastman Kodak Company, Rochester, NY) for
visualization of protein bands.s.A: CSE1LmRNAexpression increases approximately twofold betweennormal
mRNA expression increases fromNR and all stages of CRC (Astler-Coller stages
ﬁcantly up-regulated in NR/AD pairs in different patients. ***P < 0.001.
ajp.amjpathol.org - The American Journal of Pathology
Figure 2 CSE1L expression in normal, ade-
noma, and colorectal carcinoma (CRC). AeC: CSE1L
expression is induced in adenomas (A) and colo-
rectal carcinoma (B), but not in normal colon
epithelial cells (C). D: Quantiﬁcation of CSE1L
expression using the Allred scoring system shows a
signiﬁcantly increased staining score between
normal and CRC and between normal and adenoma
(P Z 0.01). E: Quantiﬁcation of CSE1L expression
is also signiﬁcantly increased between adenoma
and CRC. ***P < 0.001. Original magniﬁcation:
100 (A); 200 (B and C).
CSE1L in Colorectal Cancer ProgressionResults
Clinical Pathologic Findings
Patients with colorectal cancer (n Z 88) were an average
age of 64 years (range, 24 to 92 years). Forty-eight patients
(54%) were male. Tumors ranged from 1.4 to 14.5 cm. Most
tumors had a polypoid and ulcerated appearance. To
correlate CSE1L expression with tumor grade, we used a
three-tier grading system. Six tumors (7%) were well
differentiated, 67 (76%) moderately differentiated, and 15
(17%) poorly differentiated (Table 1). Three (3%) colorectal
cancers were Duke’s stage A, 34 (39%) Duke’s stage B, 35
(40%) Duke’s stage C, and 16 (18%) Duke’s stage D. Only
two patients, both with rectal cancer, received preoperative
radiation to reduce the size of their tumors.
mRNA Expression of CSE1L in Colorectal Oncogenesis
To determine whether CSE1L changes in protein level during
human colorectal cancer development reﬂect changes in gene
expression, we compared CSE1L mRNA levels by gene
expression microarray in three publicly available data sets
(GEO DataSets GSE4183, GSE14333, and GSE8671) takenThe American Journal of Pathology - ajp.amjpathol.orgfrom GEO (http://www.ncbi.nlm.nih.gov/gds). In GSE4183,
the expression of CSE1L mRNA increased signiﬁcantly be-
tween NR and AD (P< 0.001) (Figure 1A) and NR and CRC
(PZ 0.02) (Figure 1A). The same increase in CSE1LmRNA
from NR compared to all stages of CRC was seen in
GSE14333 (P < 0.001) (Figure 1B). Using paired samples
from GSE8671 (Figure 1C), it was shown that adenomas
consistently overexpress CSE1L (P < 0.001).CSE1L Protein Expression in Colorectal Cancer
Progression and Patient Survival
The CSE1L staining was localized to the cytoplasm in ADs,
whereas CRCs showed both cytoplasmic and nuclear staining
(Figure 2, AeC). In CRC specimens, approximately 34% (30/
88) had weak CSE1L staining, 61% (54/88) exhibited mod-
erate to strong CSE1L staining, and 5% (4/88) were CSE1L
negative. In contrast, inNRsamples, 45% (18/40)wereCSE1L
negative and 55%(22/40) hadweakCSE1L staining. In theAD
samples, 77% (17/22) showed weak CSE1L staining, 9% (2/
22)wereCSE1Lmoderate to strongly positive, and 14% (3/22)
were CSE1L negative. There was a statistically signiﬁcant
difference found in CSE1L staining score between NR andFigure 3 CSE1L baseline expression in
NCM460, SW480, HCT116, and HT29 colorectal
cancer cell lines. A: CSE1L mRNA is expressed at
baseline in all four cell lines. The relative mRNA
expression for NCM460 and HCT116 is higher
(greater than four) than HT29 and SW480 (less
than two) cell lines. B: Western blot analysis of
CSE1L baseline protein expression shows strong
expression in NCM460, HCT116, and SW480 and
lower expression in the HT29 cell line. b-Actin was
used as a loading control.
2765
Figure 4 Knockdown of protein expression in
HCT116, SW480, and HT29 colorectal cell lines.
A: Western blot assessment of CSE1L shRNA
(SC-29908-v) knockdown of protein expression in
HCT116, SW480, and HT29 cell lines compared to
mock (M) and scramble shRNA (C). b-Actin was
used as a loading control. There is inhibition of
CSE1L protein expression when cells are treated
with shRNA compared to the mock and scramble
shRNA. B: The percentage of inhibition: HCT116
(90% knockdown), SW480 (94% knockdown), and
HT29 (86% knockdown), respectively. Densitom-
etry analysis of protein bands (arbitrary units) is
signiﬁcant in all three cell lines after CSE1L shRNA
knockdown. ***P < 0.001.
Pimiento et alCRC (P < 0.001), between NR and AD (PZ 0.01), and be-
tweenADandCRC(P< 0.001) (Figure 2,D andE).Therewas
no statistically signiﬁcant trend between CSE1L score and
tumor grade (PZ 0.77) or stage (PZ 0.25). No statistically
signiﬁcant association was found between CSE1L score and
the patients’ overall survival (P Z 0.99) or disease-free sur-
vival (PZ 0.66) using the Cox proportional hazards model.
CSE1L Knockdown Inhibits Proliferation and Colony
Formation and Induces Apoptosis
Both CSE1L mRNA and protein were expressed at baseline
in multiple colorectal cancer cell lines (HCT116, SW480,Figure 5 CSE1L shRNA interference in HCT116, HT29, and SW480 cell line pr
cancer cells leads to signiﬁcant inhibition of proliferation. B: Cell colonies treate
growth versus colonies treated with control shRNA. C: shRNA causes signiﬁcant
sorbent assay in HCT116, HT29, and SW480 cell lines compared to the mock and
2766and HT29) (Figure 3, A and B). Using CSE1L shRNA, we
were able to signiﬁcantly inhibit the protein expression in
these cell lines and evaluated the functional implication of
this inhibition. The percentage of CSE1L protein inhibition
in HCT116 was 90% knockdown; SW480, 94% knock-
down; and HT-29, 86% knockdown (Figure 4A). Densi-
tometry analysis of protein bands in arbitrary units was
signiﬁcant in all three cell lines after CSE1L shRNA
knockdown (P < 0.001) (Figure 4B). Proliferation was
signiﬁcantly inhibited in HCT116, HT29, and SW480 cells
(Figure 5A). Down-regulation of CSE1L was also associ-
ated with inhibition of colony formation in all three cell
lines (P < 0.01, P < 0.05, and P < 0.01) (Figure 5B).oliferation and survival. A: CSE1L shRNA interference in human colorectal
d with CSE1L shRNA show signiﬁcant reduction in anchorage-independent
induction of apoptosis, as measured by death cell enzyme-linked immuno-
scramble shRNA groups. *P < 0.05, **P < 0.01.
ajp.amjpathol.org - The American Journal of Pathology
CSE1L in Colorectal Cancer ProgressionApoptosis, after inhibition of CSE1L, was induced, as
measured by cell death enzyme-linked immunosorbent
assay, in HCT116, HT29, and SW480 cell lines (Figure 5C)
compared with scramble shRNA (P < 0.05, P < 0.05, and
P < 0.01, respectively).
Discussion
CSE1L expression is necessary for accurate alignment of
chromosomes, which assures genomic stability during cell
division. Therefore, aberrant CSE1L expression may affect
genomic stability, a feature that is lost in cancer. Previous
studies of CSE1L protein expression in colorectal cancer
have also been investigated in selected cell lines.19 In this
study, we show mRNA and protein expression of CSE1L in
human colorectal tissues using multiple data sets and mul-
tiple cell lines. Interestingly, when comparing the progres-
sion from normal mucosa to adenomas to colorectal cancers,
we noticed a signiﬁcant increase in CSE1L expression at
both the mRNA and protein level during the transition from
normal mucosae to adenoma. High expression of CSE1L
protein was also noted in selected human colon cancer cell
lines (HCT116, HT29, and SW480). These results are in
agreement with prior studies12,19 and are consistent with the
notion that CSE1L protein expression may play a role in the
early stages of colorectal tumorigenesis. Interestingly, we
observed a change in CSE1L staining intensity and cellular
localization during the transition from adenoma to colorectal
cancer.
Our observation of concomitant nuclear CSE1L stain in
colorectal cancers may reﬂect the CSE1L function as a
transport factor. It is known that the N-terminal domain of
CSE1L is homologous to the Ran-binding domain in b-
importin.20,21 Furthermore, Kutay et al22 have shown that
CSE1L is necessary for recycling of importin-a from the
nucleus to the cytosol. Importin recycling is required for
nuclear transport of a variety of proteins, including those
necessary for mitosis or apoptosis.23 Seiden-Long et al24
studied a human colorectal cancer TMA containing sam-
ples from normal colonic mucosa, primary, and metastatic
colorectal tumors; adenomas were not included. Similar to
our study, the investigators reported nuclear and cyto-
plasmic distribution of the stain in the tumors, but the
authors did not specify whether such localization was seen
in the normal and adenomatous samples as well.
Tai et al25 previously reported that high cytoplasmic
staining of CSE1L in a CRC tumor was associated with
advanced cancer stage and depth of tumor penetration.
There was no relationship between nuclear CSE1L staining
and clinical manifestations, including tumor stage.
In our study, we found no correlation between CSE1L
expression with tumor grade and stage. This lack of corre-
lation may be because of the fact that our TMA contained
approximately 67% of moderately differentiated and only
7% of well-differentiated tumor samples. Similarly, the
TMA had only 16 Duke’s stage D primary CRC and noThe American Journal of Pathology - ajp.amjpathol.orgmetastatic CRC samples. This did not allow appropriate
correlation with tumor grade and stage.
CSE1L expression has been previously studied in meta-
static tumors. A signiﬁcant reduction of CSE1L levels has
been observed when comparing primary to metastatic tu-
mors.12 In primary CRC, it has been shown that depletion of
CSE1L expression signiﬁcantly reduced the adhesive ca-
pacity, while increasing migration and invasion of HCT116
and SW480 CRC tumor cell lines compared with negative
controls.12 It has been shown that the COOH-terminal
domain of CSE1L interacts with metalloproteinases-
2econtaining vesicles.26 Interestingly, these authors
demonstrated an increased level of CSE1L in the sera of
patients with metastatic colorectal cancer.26 E-cadherin
mRNA levels and intercellular adhesion molecule-1 were
signiﬁcantly reduced after siRNA knockdown, potentially
increasing tumor invasion and metastasis. In contrast, there
was a sevenfold to eightfold increase in matrix
metalloproteinase-9 levels in HCT116 and SW480, respec-
tively.12 These ﬁndings are signiﬁcant in light of previous
studies showing that CRC tumors expressing high cyto-
plasmic CSE1L were associated with an overall poor patient
survival rate.25
Our study was designed to test the changes in CSE1L
mRNA and protein expression during the progression from
normal colonic mucosa to carcinoma using human CRC gene
expression proﬁling and human colorectal tissue samples.
We observed a statistically signiﬁcant increase in CSE1L
expression during the progression of colorectal cancer. The
results of our in vitro experiments are in agreement with
previous studies.5,12,27 The knockdown of CSE1L using
shRNA on multiple colorectal cancer cell lines was asso-
ciated with inhibition of cell proliferation and cell growth in
soft agar and in induction of apoptosis.
Our ﬁndings provide additional support for CSE1L as a
potential target for treatment of CRC.Acknowledgments
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